An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation

Immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 axis have changed the treatment paradigm for advanced solid tumors; however, many patients experience treatment resistance. In preclinical models 4-1BB co-stimulation synergizes with ICI by activating cytotoxic T- and NK-cell-mediated anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Muik, Alexander, Altintas, Isil, Gieseke, Friederike, Schoedel, Kristina B, Burm, Saskia M, Toker, Aras, Salcedo, Theodora W., Verzijl, Dennis, Eisel, David, Grunwitz, Christian, Kranz, Lena M, Vormehr, Mathias, Satijn, David P.E., Diken, Mustafa, Kreiter, Sebastian, Sasser, Kate, Ahmadi, Tahamtan, Türeci, Özlem, Breij, Esther C.W., Jure-Kunkel, Maria, Sahin, Ugur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855865/
https://www.ncbi.nlm.nih.gov/pubmed/35186440
http://dx.doi.org/10.1080/2162402X.2022.2030135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855865/
https://www.ncbi.nlm.nih.gov/pubmed/35186440
http://dx.doi.org/10.1080/2162402X.2022.2030135

Ejemplares similares